Many different types of proteins can lead to amyloid deposits, but only a few of them can cause major health problems. While amyloid refers to an abnormal protein build-up around organs, the reason for it is still not found. The two most common types of amyloidosis are light-chain amyloid disease and wild-type ATTR amyloidosis (ATTR). Of these, the light chain is the most diagnosed type, especially in the field of cardiology. ATTR is genetic but only witnessed in countries such as Portugal and Spain, where certain communities carry genes of amyloid.
First centre in India
The centre is aimed at evaluating and treating patients suspected of amyloidosis to diagnose different kinds of variants such as AL, ATTR, and AA, among others.
The patients, he said, can now be treated in a comprehensive way, similar to the dedicated amyloid centres in Europe and US.
Amyloid proteins deposit mostly inside the knee, followed by the hands, wrists, elbow, hip, and ankle.
Amyloid deposition in the kidney can affect its ability to filter and excrete waste. This can lead to high levels of protein in the urine. Accumulation of amyloid proteins in the gastrointestinal system may cause weight loss, diarrhea, abdominal pain, and heartburn (gastrointestinal reflux). A rare development is amyloid purpura, which includes bleeding with bruising around the eyes.
The diagnosis of amyloidosis disease may be suspected when amyloid protein is found in urine, or when peripheral nerves do not function properly. The doctor may conduct tissue biopsy, blood and urine tests, and imaging tests such as ultrasound, echocardiogram, electrocardiogram, MRI, and CT scan.
The treatment for amyloidosis is dealt with by a huge team of doctors as it affects various organs of the body. The term is termed as a multidisciplinary team, which includes a haematologist (who specialises in blood disorders), a cardiologist, a gastroenterologist, a pulmonologist, a nephrologist, and a neurologist.
Treatment with high-dose melphalan, a chemotherapy agent, followed by stem cell transplantation has shown promise in early studies and is recommended for stage I and II AL amyloidosis.
For cardiac amyloidosis, there is no cure yet. It is more common in men than in women and it affects older people.